Skip to content
Menu

Zai Lab Limited ZLAB

Full chart Compare
Set alert

Price alert · ZLAB

All alert types
21.92 USD -0.19 (-0.86%)

Regular-session close

21.99 +0.07 +0.32%

After hours · Nov 19, 4:42 PM ET

21.70 Day range 22.27
15.96 52-week range 29.02
YTD
+24.26%
1 year
+6.93%

5D -3.54 (-13.39%)

2426ThuFriMonTueWed22.90
Market cap
2.74B
Revenue (ttm)
441.73M
Profit margin
-44.91%
EPS (ttm)
-1.80
Shares out
124.84M
Forward P/E
-10.92
YTD return
+24.26%
1-year return
+6.93%
50-day average
24.46
200-day average
21.40
Volume
611.42K
Avg volume
996.56K
Open
21.94
Previous close
22.11
Day's range
21.70 – 22.27
52-week range
15.96 – 29.02
Beta
0.72
Analysts
Strong Buy
Price target
34.21 (+56.1%)
Earnings date
Feb 25, 2027

Key statistics

Enterprise value
2.19B
Price / sales
6.20
Price / book
4.38
Revenue growth
-6.80%
Free cash flow
-120.17M
Total cash
559.66M
Total debt
267.45M
Return on equity
-29.99%
Short % of float
6.64%

Fundamental scorecard

8 of 25 checks passed on ZLAB’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ZLAB Revenue — quarterly 108.21M
ZLAB Net income — quarterly -46.14M
ZLAB EPS — quarterly -0.40

Earnings

ZLAB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.53895———
Nov 5, 2026Sep 30, 2026-0.59177-0.41+0.18+30.72%
Aug 6, 2026Jun 30, 2026-0.67939-0.46+0.22+32.29%
May 7, 2026Mar 31, 2026-0.52616-0.46+0.07+12.57%
Feb 26, 2026Dec 31, 2025-0.44-0.46-0.02-4.55%
Nov 6, 2025Sep 30, 2025-0.28-0.33-0.05-17.86%

Upgrades / downgrades

ZLAB analyst upgrades and downgrades
DateFirmActionFromTo
Aug 7, 2026CitigroupmainBuyBuy
May 8, 2026CitigroupmainBuyBuy
Mar 18, 2026JP MorganmainOverweightOverweight
Feb 27, 2026Cantor FitzgeraldmainOverweightOverweight
Feb 5, 2026JP MorganmainOverweightOverweight
Jan 7, 2026UBSinit—Buy

About Zai Lab Limited

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Sector
Healthcare
Industry
Biotechnology
Country
China

News

Your note

Sign in to keep a note on ZLAB — it syncs with the Stock Master app.

Insider holders

ZLAB insider holders
InsiderRelationLatest transactionDateShares held
AMADO RAFAELPresidentSaleApr 5, 202657,022
DIEKMAN JOHN DAVIDDirectorStock Award(Grant)Jun 16, 2026122,140
DU YING SAMANTHAChief Executive OfficerConversion of Exercise of derivative securityJul 1, 20261,221,400
GAYNOR RICHARD BRIAN M.D.DirectorPurchaseNov 9, 202681,965
LEUNG NISA BERNICE WING-YUDirectorStock Award(Grant)Jun 16, 202696,297
MOULDER LEON OLIVER JR.DirectorStock Award(Grant)Jun 16, 202694,973

Institution ownership

ZLAB institution ownership
Holder% heldSharesValueReported
RTW Investments LP8.27%10,350,973226.89MSep 29, 2026
TCG Crossover Management, LLC4.98%6,229,081136.54MSep 29, 2026
Woodline Partners LP4.24%5,299,113116.16MSep 29, 2026
Adar1 Capital Management, LLC 2.70%3,381,36474.12MSep 29, 2026
RA Capital Management, L.P.2.25%2,815,54361.72MSep 29, 2026
Goldman Sachs Group Inc1.53%1,912,53241.92MSep 29, 2026

Fund ownership

ZLAB fund ownership
Holder% heldSharesValueReported
BARON SELECT FUNDS-Baron Emerging Markets Fund1.10%1,370,90430.05MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.59%740,49416.23MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund0.27%331,7807.27MSep 29, 2026
abrdn World Healthcare Fund0.25%311,2946.82MJun 29, 2026
Tema ETF Trust-Tema Oncology ETF0.13%161,2783.54MAug 30, 2026
ALPS ETF TRUST-ALPS Medical Breakthroughs ETF0.11%134,2672.94MAug 30, 2026